Smoking cessation in patients with respiratory disease: existing treatments and future directions.
paper
Cited
Public
Unavailable
- Authors
- Rigotti, Nancy A
- Year
- 2013
- Journal
- The Lancet. Respiratory medicine
- PMID
- 24429130
- DOI
- 10.1016/S2213-2600(13)70063-8
Tobacco use is a leading cause of preventable death worldwide. Respiratory diseases, including chronic obstructive pulmonary disease (COPD) and lung cancer, account for a large proportion of tobacco-related deaths. Smoking cessation benefits almost all smokers, irrespective of the age at which they quit, making smoking cessation a core component of prevention and treatment of respiratory diseases. Evidence shows that psychosocial counselling and pharmacotherapy are effective smoking cessation methods and are most effective when used together. The first-line drugs licensed to aid smoking cessation (nicotine replacement therapy, bupropion, and varenicline) are effective in patients with COPD. Efforts are underway to improve the efficacy of existing treatments and increase the proportion of smokers who try to quit, and who use treatment when doing so. However, existing smoking cessation counselling and drugs are among the most cost-effective clinical preventive services available. Incorporation of such treatment into routine clinical practice is essential for provision of high-quality care to all patients, especially those with respiratory disease.
No figures extracted from this document.
No chunks β full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
No citations found.
In this knowledge base
| Title | Year | PMID |
|---|---|---|
| Genetic variation (CHRNA5), medication (combination nicotine replacement therapy vs. varenicline), and smoking cessation. | 2015 | 26142345 |
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Mortality prevention as the centre of COPD management. | Papaioannou AI et al. | β | 2024 | β |
| Reducing the risk of death - a possible outcome in COPD patients. | Maniscalco M et al. | β | 2024 | β |
| The Relation between Cigarette Smoking and Development of Sepsis: A 10-year Follow-up Study of Four Million Adults from the National Health Screening Program | Lee EH et al. | β | 2024 | β |
| The Relation Between Cigarette Smoking and Development of Sepsis: A 10-Year Follow-Up Study of Four Million Adults from the National Health Screening Program. | Lee EH et al. | β | 2024 | β |
| Common assumptions in tobacco control that may not hold true for South-East Asia. | Siddiqi K et al. | β | 2023 | β |
| Non-pharmacological interventions for smoking cessation: analysis of systematic reviews and meta-analyses. | Nian T et al. | β | 2023 | β |
| Patient-Reported Receipt of Oncology Clinician-Delivered Brief Tobacco Treatment (5As) Six Months following Cancer Diagnosis. | Price SN et al. | β | 2023 | β |
| Smoking-related dysregulation of plasma circulating microRNAs: the Rotterdam study. | KarabegoviΔ I et al. | β | 2023 | β |
| Effect of Fasting on Smoking Addiction: A Multicentered Primary Care Research. | Γnal M et al. | β | 2022 | β |
| Nitric Oxide Linked to mGluR5 Upregulates BDNF Synthesis by Activating MMP2 in the Caudate and Putamen after Challenge Exposure to Nicotine in Rats. | Kim J et al. | β | 2022 | β |
| Smoking cessation programme in hospitalised patients due to acute respiratory disease. | Guerra SIS et al. | β | 2022 | β |
| The prevalence and associated factors of shisha use among smokers attending three primary healthcare centers in Qatar, 2020. | Rashed MHI et al. | β | 2022 | β |
| Vaping-Associated Lung Injury: A Review. | O'Callaghan M et al. | β | 2022 | β |
| High SARS-CoV-2 seroprevalence in persons experiencing homelessness and shelter workers from a day-shelter in SΓ£o Paulo, Brazil. | do Couto AC et al. | β | 2021 | β |
| Patient-Level Factors Associated with Oncology Provider-Delivered Brief Tobacco Treatment Among Recently Diagnosed Cancer Patients. | Neil JM et al. | β | 2020 | β |
| Smoking and COVID-19: Similar bronchial ACE2 and TMPRSS2 expression and higher TMPRSS4 expression in current versus never smokers. | Voinsky I et al. | β | 2020 | β |
| Cigarette Smoking Is Negatively Associated with the Prevalence of Type 2 Diabetes in Middle-Aged Men with Normal Weight but Positively Associated with Stroke in Men. | Wang S et al. | β | 2019 | β |
| Effect of tobacco smoking on the epigenetic age of human respiratory organs. | Wu X et al. | β | 2019 | β |
| Efficacy of guided self-change for smoking cessation in chronic obstructive pulmonary disease patients: A randomized controlled clinical trial. | Zarghami M et al. | β | 2019 | β |
| Interactions of Glutamatergic Neurotransmission and Brain-Derived Neurotrophic Factor in the Regulation of Behaviors after Nicotine Administration. | Kim J et al. | β | 2019 | β |
| Pharmacological Management of Chronic Obstructive Lung Disease (COPD). Focus on Mutations - Part 1. | Russo P et al. | β | 2019 | β |
| mGluR2/3 mediates short-term control of nicotine-seeking by acute systemic N-acetylcysteine. | Moro F et al. | β | 2018 | β |
| npj Primary Care Respiratory Medicine broadens its focus to include global respiratory health, tobacco control and implementation science. | Siddiqi K et al. | β | 2017 | β |
| Trends in utilization of smoking cessation agents before and after the passage of FDA boxed warning in the United States. | Shah D et al. | β | 2017 | β |
| Air pollution and chronic airway diseases: what should people know and do? | Jiang XQ et al. | β | 2016 | β |
| A prospective and retrospective analysis of smoking behavior changes in ever smokers with high risk for lung cancer from New Mexico and Pennsylvania. | Leng S et al. | β | 2016 | β |
| Health Promotion Methods for Smoking Prevention and Cessation: A Comprehensive Review of Effectiveness and the Way Forward. | Golechha M | β | 2016 | β |
| Pharmacological and genetic reappraisals of protease and oxidative stress pathways in a mouse model of obstructive lung diseases. | Shuto T et al. | β | 2016 | β |
| Smoking control: challenges and achievements. | Silva LC et al. | β | 2016 | β |
| The management of asthmatic smokers. | Chatkin JM et al. | β | 2016 | β |
| Budgetary impact analysis on funding smoking-cessation drugs in patients with COPD in Spain. | JimΓ©nez-Ruiz CA et al. | β | 2015 | β |
| Environmental aspects of congenital scoliosis. | Li Z et al. | β | 2015 | β |
| Genetic variation (CHRNA5), medication (combination nicotine replacement therapy vs. varenicline), and smoking cessation. | Chen LS et al. | β | 2015 | β |
| Pharmacology of novel treatments for COPD: are fixed dose combination LABA/LAMA synergistic? | Spina D | β | 2015 | β |
| Results of an inpatient smoking cessation program: 3-month cessation rate and predictors of success. | Kim SH et al. | β | 2015 | β |
| Systematic review and meta-analysis of the impact of depression on subsequent smoking cessation in patients with chronic respiratory conditions. | Ho SY et al. | β | 2015 | β |
| Electronic cigarettes. Potential harms and benefits. | Drummond MB et al. | β | 2014 | β |
| Electronic cigarettes: 'vaping' has unproven benefits and potential harm. | Lam DC et al. | β | 2014 | β |
| Evaluation of risk factors for arytenoid dislocation after endotracheal intubation: a retrospective case-control study. | Shen L et al. | β | 2014 | β |
| The use of expensive technologies instead of simple, sound and effective lifestyle interventions: a perpetual delusion. | Carlos S et al. | β | 2014 | β |
| Smoking cessation and respiratory disease in low-income and middle-income countries. | Dogar O et al. | β | 2013 | β |